🇺🇸 FDA
Pipeline program

AKCEA-ANGPTL3-LRX

ISIS 703802-CS4

Phase 2 small_molecule terminated

Quick answer

AKCEA-ANGPTL3-LRX for Homozygous Familial Hypercholesterolemia is a Phase 2 program (small_molecule) at IONIS PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
IONIS PHARMACEUTICALS INC
Indication
Homozygous Familial Hypercholesterolemia
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials